Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation

WHO issues warning on the surge of new age gateway devices among children

Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use

Pfizer presents marstacimab Phase 3 Data at ASH 2023

Demonstrate significant bleed reduction in hemophilia A and B

ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346

First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes

European Commission approves Pfizer’s Elrexfio for multiple myeloma

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone

AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes

STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme

Developing entrepreneurship in Ayush Sector is a priority area: Ayush Minister

Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta